▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

New Data Show CCS’s Predictive Analytics and Intervention Platform Is Highly Effective in Driving Continuous Glucose Monitoring Adherence in Medicare Population

#chroniccare--CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s p...

Business Wire

More than $10 million in taxpayer dollars saved by proactively addressing CGM nonadherence in thousands of Medicare patients with diabetes

More than a third of this high-risk population experiences improved adherence resulting from AI-powered personalized interventions

ST. PETERSBURG, Fla.: #chroniccare--CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s proprietary AI-enabled predictive analytics and intervention platform — PropheSee™ — effectively identified approximately 28 percent of 55,000 Medicare fee-for-service (FFS) patients at risk of lapsing on continuous glucose monitoring (CGM) therapy. As a result of applying CCS’s predictive analytics and intervention platform to this high-risk Medicare population, more than $10 million in taxpayer dollars have already been saved.

After identifying more than 14,400 at-risk patients, CCS then segmented them into defined personas based on patient-specific clinical, socioeconomic, and behavioral data. Customized interventions designed to effect lasting behavior change were then deployed, leading to millions of taxpayer dollars being saved in unused CGM devices and unnecessary care for this high-cost, high-risk population.

The following two interventions illustrate the striking impact of PropheSee™ on Medicare patients’ CGM adherence:

  • Adherence improved 46% when patients received messages aligned with provider trust.
  • Rural patients showed a 30% adherence boost when reminded of at-home support options.

PropheSee™, launched in June 2024, was awarded “Best Predictive Analytics Solution” as part of the MedTech Breakthrough Awards on May 8, 2025 — a prestigious international awards program that recognizes exceptional digital health and medical technology products and companies. The platform is a first-of-its-kind AI-powered predictive and intervention platform that actively identifies patients most at risk of stopping usage of their CGM within 30 days with 85% accuracy and deploys highly personalized interventions to keep these patients on track.

By moving the signal and intervention upstream with PropheSee™, CCS can help patients and providers stay one step ahead of nonadherence. By keeping people on CGM therapy who may otherwise have experienced adverse consequences of poor glycemic control, health plans and risk-bearing providers can realize improved clinical outcomes, a reduction in high-cost utilization (such as emergency room visits), and savings of up to $2,200 per patient per year.

President of Lumeris Technology Solutions and CTO of Lumeris, Jean-Claude Saghbini, shared his thoughts on the value of providers like CCS expanding their role in the chronic care continuum: “For years, healthcare leaders have talked about the massive human and cost impact of being able to prevent care crises before they happen. With AI, that opportunity is now, and companies like CCS are at the forefront of supporting health plans and at-risk providers in moving from sick care to preventive care, starting with CGM adherence and the application of sound clinical and lifestyle support for the highest complexity and highest cost patient populations.”

CCS has invested heavily in reimagining the role of distributors in supporting the move to value-driven, proactive, and personalized diabetes care management. In addition to the latest Medicare FFS findings tied to the company’s predictive analytics and intervention platform, CCS has also taken a leadership role in pursuing evidence-based research that proves the value of suppliers in chronic care management. Most recently, CCS published research in Clinical Diabetes and in JMIR Diabetes — showcasing how suppliers, like CCS, produce superior outcomes compared to pharmacies when supporting patients using CGMs because they provide the clinical education and coaching needed to help patients with diabetes thrive.

“To combat the growing diabetes epidemic, we must focus on improving patient adherence and recognizing providers like CCS as essential members of the care ecosystem,” said Tony Vahedian, CEO of CCS. “As a specialized care provider, CCS has proven it can deliver vital diabetes interventions directly to the patient, improving outcomes and reducing costs for high-risk populations while saving taxpayers millions.”

To learn more about CCS’s transition from traditional supplier to an intelligent, holistic chronic care management platform that bridges costly gaps in patient-facing chronic care education and coaching, visit ccsmed.com/predictive-analytics.

About CCS
CCS is a leading chronic care management company, providing clinical solutions and home-delivered medical supplies for those living with chronic conditions, particularly diabetes. The company works with health plans, providers, and employers to defragment the patient journey by combining the following into one seamless platform experience: medical devices, pharmaceuticals, and clinical education and coaching services. To holistically support individuals living with diabetes, CCS has advanced its AI-based machine learning and large language models to support high-risk members’ identification and timely engagement before serious adherence issues arise. CCS supports 200,000+ people living in the United States and delivers more than 1.2 million orders directly to their homes yearly. After serving individuals for more than 30 years, CCS has the relationships, experience, and data to create a new era of home-based, proactive chronic care management era. To learn more about CCS, please visit CCSMed.com; LinkedIn.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Securonix Acquires ThreatQuotient to Deliver Industry’s Broadest and Deepest…

Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of…

PubNub Evolves Its Platform with AI-Native Development, Real-Time Moderation,…

PubNub, the leader in real-time interactive apps, unveiled the next evolution of its platform. It introduces AI-native development, real-time decision…

Confidential Computing Poised for Explosive Growth as Anjuna Secures Three…

Anjuna, a leader in Confidential Computing and AI Data Fusion Clean Rooms, today announced the addition of a new top five global bank to its growing roster…

Glean Raises $150M Series F at $7.2B Valuation to Accelerate Enterprise…

Work AI leader Glean today announced it raised $150 million in Series F financing, bringing its valuation to $7.2 billion. The round was led by Wellington…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!